linkedin Created with Sketch. twitter Created with Sketch. instagram Created with Sketch.
Shape
← Back to portfolio Porfolio / PredictImmune

PredictImmune

Developer of pioneering prognostic tools

Company overview

Founded in May 2017 and based at the Babraham Research Campus in Cambridge, PredictImmune develops pioneering tools for guiding treatment options in immune-mediated inflammatory diseases like Crohn’s and ulcerative colitis (IBD).

Based on ten years of research at Cambridge University, PredictImmune’s test kits help both clinicians and patients to understand, at the point of diagnosis, the likely course of disease and opens the possibility of better treatment choices from the outset.

Website
PredictImmune

Company information

Head office
  • Cambridge
CEO
  • Paul Kinnon
Chair
  • Andrew P Sandham
BGF office
BGF team
Investment date
  • Jul 2019
Total BGF investment
  • £4 million

Business funding insights

March 2021 Insights

BGF explains: initial public offerings (IPOs)

We explain what’s meant by an initial public offering (IPO), also known as listing or ‘going public’.
Business funding
March 2021 Insights

When to pursue debt refinancing and why

You may find that refinancing or renegotiating your business debts can put you in a stronger financial position. Look at…
Business funding
March 2021 Insights

Women who lead growing businesses: a survey

Our research reveals female entrepreneurs in the growth economy are concerned about the pandemic and Brexit, but remain resilient and motivated to achieve growth
Business funding